The present invention is directed to compounds represented by the
following structural formula, and pharmaceutically acceptable salts
thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the
group consisting of (C.sub.1-C.sub.6) alkyl, (C.sub.1-C.sub.6) alkenyl,
aryl (C.sub.0-C.sub.4) alkyl, aryloxy (C.sub.0-C.sub.4) alkyl, arylthio
(C.sub.0-C.sub.4) alkyl, and further wherein when R5 is alkyl, R5 can
optionally combine with W to form a 6 membered cycloheteroalkyl ring that
is fused with the oxazole or thiazole ring to which the R5 group is
attached; (b) R9 is selected from the group consisting of C.sub.1-C.sub.5
alkyl, C.sub.1-C.sub.5 alkenyl, and arylC.sub.0-C.sub.3alkyl. (c) T.sub.1
is selected from the group consisting of C and N, (d) W is selected from
the group consisting of CH.sub.2, C(O)N(R21), N(R21), N(R21)CH.sub.2, O,
OCH.sub.2, S, and SO.sub.2; and (e) X is selected from the group
consisting of C, CH.sub.2C, and CCH.sub.2 1
